Poolbeg Pharma Share Discussion Threads

[burtond1] 04/10/2023 11:27

Worth an watch! Below, an interview featuring Jeremy Skillington and Emily Liu, following her industry piece on AI:https://www.youtube.com/watch?v=TWl5aCf-seo

[inaminute] 02/10/2023 09:34

Yes. Much better to be stuck just in here with all the others from One Flew Over the Cuckoos Nest

[arlington chetwynd talbott] 30/9/2023 15:25

Sorry to hear that there is a POLB Telegram. The last thing investors in small companies like POLB need is to get stuck in one of those kind of echo chambers.

[klosters65] 29/9/2023 15:31

Agree . Very strange, misleading on trading, goings on the there. I put the above post, on POLB telegram

[burtond1] 29/9/2023 07:55

Great news for POLB !!!The European Patent Office has decided against proceeding with the scheduled hearing relating to the opposition to the Company's Immunomodulator I European patent. This follows the withdrawal of the patent opposition by a third party as announced on 19 September 2023. This favourably concludes this matter with the patent maintained as granted.https://www.londonstockexchange.com/news-article/POLB/favourable-conclusion-of-patent-opposition/16145276

[troutisout] 29/9/2023 07:11

Hopefully this now marks an end to this and the chance to conclude a deal for POLB001

[burtond1] 27/9/2023 10:35

Research note on #POLB 19p price target Poolbeg Pharma PLC7.2p LTarget Price: 19.0Poolbeg Pharma specialises in the development of innovative medicines to address the unmet need in infectious and other prevalent diseases. Poolbeg has a disciplined portfolio approach to mitigate risk, accelerate drug development, and enhance investor returns. The Company simultaneously advances multiple programmes in cost-effective clinical trials, rapidly generating early human safety and efficacy data to enable early partnering / out-licensing, with the funds generated reinvested in the pipeline. Poolbeg also uses AI to interrogate human challenge trial data sets to quickly identify new targets and drugs, and in-license near or in the clinic medicines, leading to faster development and greater commercial appeal. The Company is targeting the growing infectious disease market. In the wake of the COVID-19 pandemic, infectious disease has become one of the fastest growing pharma markets and is expected to exceed $250bn by 2025. Through opportunistic identification of assets which complement Poolbeg's existing pipeline, the Company is progressing programmes in oncology and metabolic syndromes; adding disease areas with significant addressable markets. With its initial assets from hVIVO plc (formerly Open Orphan plc), an industry leading infectious disease and human challenge trials business, Poolbeg has access to knowledge, experience, and clinical data from over 20 years of human challenge trials. The Company is using these insights to acquire new assets as well as reposition clinical stage products, reducing spend and risk. Amongst its portfolio of exciting assets, Poolbeg has a small molecule immunomodulator for severe influenza and other acute inflammatory conditions (POLB 001) which produces a highly significant reduction in p38 MAP kinase driven cytokines in a clinical setting; a first-in-class, intranasally administered RNA-based immunotherapy for respiratory virus infections (POLB 002); and a vaccine candidate for Melioidosis (POLB 003). The Company is also developing two Oral Delivery Programmes and is progressing two Artificial Intelligence (AI) Programmes to add promising new assets to its pipeline.

[burtond1] 27/9/2023 07:06

The #POLB CEO will be presenting at the @DDWJournal webinar on 10 October 2023AI and Lab Automation: What are the key benefits and latest innovations?Register here:https://www.ddw-online.com/webinar-key-benefits-and-latest-innovations-in-ai-and-lab-automation-25862-202309/

[pogue] 26/9/2023 13:34

JS was an employee at Inflazone, VP of Business Development to be exact not seeing how he sold the company.
Defn of Business development officer, nothing what so ever to do with selling the company....
A Business Development Officer (BDO) is generally an executive or marketing role within an organization. BDOs are responsible for identifying, developing, and potentially closing new revenue and profit streams. A BDO's responsibilities may range from finding new customers to managing existing business relationships.

[lfdkmp] 26/9/2023 05:31

Late reported trade of 650k @6.98p (which would have been fractionally below mid at the time of the trade)

Someone is serious.

[ali47fish] 21/9/2023 07:43

no link to polb for now

[burtond1] 21/9/2023 06:56

A growing number of global pharma are investing heavily in #AI for #drugdiscovery including #POLB #POLB is to be part of this revolutionary movement with 2 successful #AI-led programs in #RSV & #Flu powered by unique human challenge trial datahttps://www.fiercebiotech.com/biotech/merck-kgaa-doubles-ai-partners-tapping-benevolentai-and-exscientia-drug-discovery-push

[sikhthetech] 20/9/2023 11:10

Muchdinero,

"We can assume it was a big pharmaceutical company trying unsuccessfully to block our patent? "


Why haven't you or your mates not mentioned there was a patent challenge by a 'big pharma' before?

There's an amicable resolution which, if anything, shows the challenger would have something to gain.

From H1 they say 3rd party pharma and they expected to win at a hearing due in Nov. So it wasn't a surprise they reached an amicable solution just before the hearing.

" It is not unusual in the pharmaceutical industry for patents to be challenged. The Immunomodulators I European patent was opposed by an anonymous third party in September 2021. The European Patent Office's ("EPO") preliminary opinion on the opposition was received in March 2023, identifying a number of items to be discussed at a hearing set for November 2023. Based on specialist advice received, and the fact that the patent went through an extensive examination process prior to being granted by the EPO, Poolbeg continues to have full confidence in the validity and strength of the patent and will vigorously defend its intellectual property to the extent required."

[klosters65] 20/9/2023 10:32

Expect the share price to Zoom. My God, we have been patient enough. Remember CF said if he had one million to invest and he had to chose one company - it would be POLB.

[klosters65] 20/9/2023 10:28

Sorry everyone. I gave you the wrong information. The presentation is at 12:30 this morning at the Mayfair hotel Charles Street.I understand that one can watch the presentation on zoom.Master Investor 12 30 to 3pm is on todayhttps://events.masterinvestor.co.uk/

[troutisout] 20/9/2023 10:24

Now getting quoted 7.177p to buy after the last buy...

[troutisout] 20/9/2023 10:20

I am getting quotes to buy at 7.05p so it looks like there have been buyers this morning, I bought yesterday at sub 7p, as did many others and they all went through below mid and showed as sells.
Personally, I see the 7p level as a bit of a base for 2023 and that means it's a good place to accumulate stock. As always DYOR....

[klosters65] 20/9/2023 09:22

I am genuinely surprised that there has been no buying.There is a presentation this evening.We know ,the share price moves very rapidly on little buying.

[parsons4] 20/9/2023 08:14

Topped up again this morning !! This is building nicely and unlike so many other small businesses they have enough cash to see them through GLA.

[burtond1] 20/9/2023 07:16

Great news for #POLB They received a notice of allowance from @JPO_JPN in relation to the Immunomodulator I patent application related to the use of p38 MAPK inhibitors for the treatment of severe #influenza. Strengthening their intellectual property protection in the territory.https://polaris.brighterir.com/public/poolbeg_pharma/news/rns/story/w6m9gqx

[joseph moran] 19/9/2023 13:05

I just bought a few and it is showing as a sell, so a lot of the sells will be buys.

[baldrick1] 19/9/2023 12:55

That was a relief news mucho ;))

[klosters65] 19/9/2023 12:07

Just a thought. Maybe a deal can be struck with whoever was trying to do the blocking.I notice, it was settled amicably.